Monday, Boston Scientific Corporation (BSX) announced an investment of $1.5 billion in return for an approximately 34 percent equity stake in MiRus LLC.
As part of the deal, Boston Scientific also received an exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloy, subject to additional payments and the completion of certain milestones.
Boston Scientific may exercise the option to acquire the MiRus TAVR business by making additional aggregate cash payments totaling $3 billion, resulting in a full ownership of the business.
Notably, investment in MiRus is expected to be immaterial to adjusted earnings per share for Boston Scientific in 2026.
In the pre-market hours, BSX is trading at $53.45, up 1.42 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.